JAKARTA – Two new investors will reportedly make their ways into PT Kimia Farma (Persero) Tbk (KAEF) through their participation in the issuance of mandatory convertible bonds from February 14 to 21, 2023.

Based on the prospectus quoted today (2/2), PT Bio Farma (Persero) is still listed as the owner of 499.99 billion series B shares or 90.25% of total issued and paid-up capital of KAEF, while public investors claim another 9.975%. KAEF’s authorised capital is IDR 2 trillion, while its total issued and paid-up capital is worth IDR 555.40 billion. Then, the stock in its portfolio reaches IDR 1.44 trillion of worth.

Then, the shares offered through this convertible bonds issuance are 325.10 million units of IDR 100 each. The price will be set to IDR 1,025 per share, targeting to raise a total of IDR 333.23 billion.

Bio Farma decided not to exercise any of its portion and reassigned 146.34 million shares to PT Akar Investasi Indonesia (AII) and CIZJ Limited (CIZJ). With the offering price set to IDR 1,025 per share, KAEF will potentially raise IDR 299.97 billion.

Then, the remaining shares from unconverted bonds will automatically turn into additional series B shares. (LK/ZH)